Episode
Buy Hold Sell: Flesh wound or flatline? 7 ASX healthcare stocks dissected
- Published
- May 7, 2026
- Duration seconds
- 1295
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/buy-hold-sell-by-livewire-markets-599577/episodes/buy-hold-sell-flesh-wound-or-flatline-7-asx-healthcare-stocks-dissected/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/buy-hold-sell-by-livewire-markets-599577/buy-hold-sell-flesh-wound-or-flatline-7-asx-healthcare-stocks-dissected.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
For years, the ASX healthcare sector was the picture of health itself - a compounding growth story that investors treated as a set-and-forget holding. Then came a brutal twelve months. The sector has shed nearly 40%, with former darlings and long-standing heavyweights hitting lows not seen in a decade. The causes aren't simple, and perhaps most disorienting is the ‘defensiveness’ that investors paid a premium for has simply stopped working. As one of our guests in this week's episode says, to quote The Castle - "The vibe is off." To work through the prognosis, Livewire's Anna Dadic is joined by Julia Weng of Paradice Investment Management and Hamish FitzSimons of AllianceBernstein. In this episode, five sector stocks are put under the microscope. Our guests unpack the sell-off, make the case for where the stock-picking opportunities lie, and as always, share a high-conviction pick of their own. This episode was filmed Wednesday 6th May 2026.